Three highly experienced partners Voxcan, Bioversys, and Biosystems Technology are collaborating on an R&D project to produce a solution that transform antimicrobial drug discovery through a seamless platform for effective in vitro and real-time in vivo drug candidate screening and target validation.
IMPACT2 aims to develop novel translational research tools. We will deliver a single platform, composed of three components, which will be used to expedite development of antimicrobial resistance (AMR) and anti-virulence drugs.
